Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data
BioPharma Drive: Drug Pricing
JULY 15, 2024
Updated results show the biotech's RAS inhibitor shrank pancreatic tumors in 20% to 25% of study participants, but with high rates of side effects like rash and nausea.
Let's personalize your content